M
Mark F. Brady
Researcher at Roswell Park Cancer Institute
Publications - 107
Citations - 14496
Mark F. Brady is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Gynecologic oncology & Ovarian cancer. The author has an hindex of 46, co-authored 105 publications receiving 12696 citations. Previous affiliations of Mark F. Brady include University of California, Los Angeles & Utrecht University.
Papers
More filters
Journal ArticleDOI
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Q. Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: In this article, a double-blind, placebo-controlled, phase 3 trial was conducted to evaluate the effect of bevacizumab and paclitaxel on progression-free survival in patients with stage III or stage IV epithelial ovarian cancer.
Journal ArticleDOI
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Q. Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: This multinational double-blind placebo-controlled trial was designed to evaluate the addition of bevacizumab to standard front-line ovarian cancer therapy in patients with stage III or IV epithelial ovarian cancer.
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer EDITORIAL COMMENT
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: The use of bevacizumab during and up to 10 months after carboplatin and paclitaxel chemotherapy prolongs the median progression-free survival by about 4 months in patients with advanced epithelial ovarian cancer.
Journal ArticleDOI
Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials
Claire L Vale,Jayne F. Tierney,Lesley A. Stewart,Mark F. Brady,Ketayun A. Dinshaw,Anders Jakobsen,Mahesh K. B. Parmar,Gillian Thomas,Ted Trimble,David S. Alberts,Hongwei Chen,Slobodan Cikaric,Patricia J. Eifel,Melahat Garipagaoglu,Henry M. Keys,Nermina Kantardzic,Punita Lal,Rachelle Lanciano,Felix Leborgne,Vicharn Lorvidhaya,Hiroshi Onishi,Robert Pearcey,E Pras,Kenneth B. Roberts,Peter G. Rose,Charles W. Whitney +25 more
TL;DR: These results endorse the recommendations of the NCI alert, but also demonstrate their applicability to all women and a benefit of non-platinum-based chemoradiotherapy.
Journal ArticleDOI
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.
William J. Hoskins,William P. McGuire,Mark F. Brady,Howard D. Homesley,William T. Creasman,Michael L. Berman,Harrison Ball,Jonathan S. Berek +7 more
TL;DR: Among patients with suboptimal (> 1 cm residual disease) epithelial ovarian cancer, those who have small diameter residual disease tend to survive longer thanThose who have larger residual disease, and size does not affect prognosis appreciably.